Disclaimer, Terms & Sources
Please read before relying on anything in this app.
Not medical advice
Precision Protocol is an educational and record-keeping tool. It does not diagnose, treat, cure, or prevent any condition, and nothing in it is a prescription or a recommendation to use any compound. Many peptides listed here are research chemicals that are not approved for human use in your country. Dose ranges are summaries of published literature, not instructions. Always work with a licensed clinician who knows your history, and never change a prescribed regimen based on this app.
Terms of use
By using Precision Protocol you confirm you are at least 18 years old and accept full responsibility for any decision you make about your own health.
The app is provided "as is", without warranty of any kind. Calculations, schedules, vial estimates, and reminders may be inaccurate, delayed, or missed — including due to device settings, browser limits, or service outages. Never rely on a reminder as the sole safeguard for a critical medication.
You may not use the app to sell, market, or distribute controlled or unapproved substances. We may change or discontinue features at any time.
Your data & privacy
Your medications, doses, vials, and calculations are stored in your own account and are only readable by you — access rules are enforced at the database level, not just in the app.
If you use the app without creating an account, your data is tied to a guest profile on that device. Adding an email and password in Settings converts that guest profile into a real account and keeps everything you've entered.
Notification subscriptions store only the anonymous endpoint your browser issues, so reminders can be delivered. Delete them any time by turning reminders off.
Where our research information comes from
Compound profiles are compiled from peer-reviewed literature, registered trial protocols, and regulatory labeling. Where community practice differs from published protocols, we say so explicitly and default to the more conservative dose.
- PubMed / MEDLINEPrimary literature for mechanism of action, half-life, and trial dosing.
- ClinicalTrials.govRegistered trial protocols and dose-escalation schedules.
- DailyMed (FDA labeling)Approved prescribing information for licensed medications.
- NEJM — Retatrutide Phase 2 (2023)Efficacy and titration data cited in the retatrutide profile.
- NEJM — Tirzepatide SURMOUNT-1 (2022)Dual GIP/GLP-1 dosing and escalation schedule.
- Endocrine Society Clinical Practice GuidelinesTestosterone and growth hormone therapy guidance.